PharmaShots | Incisive News in 3 Shots

Subscribe Now

CSL

CSL’s Hemgenix (etranacogene dezaparvovec) Receives EC’s Conditional Marketing Authorization for Hemophilia B

CSL’s Hemgenix (etranacogene dezaparvovec) Receives EC’s Conditional Marketing Authorization for Hemophilia B

February 21, 2023

CSL’s Hemgenix (etranacogene dezaparvovec-drlb) Receives the US FDA’s Approval for the Treatment of Hemophilia B

CSL’s Hemgenix (etranacogene dezaparvovec-drlb) Receives the US FDA’s Approval for the Treatment of Hemophilia B

December 22, 2022

CSL to Acquire Vifor Pharma for ~$11.7B

CSL to Acquire Vifor Pharma for ~$11.7B

December 15, 2021

Insights+: COVID-19 Healthcare News Monthly Updates - October 2020

Insights+: COVID-19 Healthcare News Monthly Updates - October 2020

October 30, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us